GRAVITY
31.3.2023 04:01:28 CEST | Business Wire | Press release
Gravity (NASDAQ: GRVY), a global game company, released its new 3D platformer game, 'ALTF42', as an Early Access version on Steam on March 31, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005345/en/
ALTF42, the permadeath-style 3D platformer sequel to ALTF4, is now available as an Early Access version on Steam starting from March 31 (Graphic: Gravity)
Gravity will take charge of services related to 'ALTF42', a permadeath-style 3D platformer genre game developed by PUMKIM, a Korean game developer, based on the global publishing know-how it has accumulated over the years. ALTF42 is the official follow-up to 'ATLF4' and features an even higher level of difficulty with more dangerous traps than the previous version. The previous one, ALTF4, gained a great popularity from users around the world, topping the list in STOVE review ratings and 70,000 concurrent viewers on Twitch.
As the game is named after the shortcut for forced shutdown, 'ALT+F4', it constantly stimulates the desire to forcefully close the game throughout the play. The game is cleared when the knight character breaks through stages with various traps and reaches a specific destination without losing its life. This game is attracting the attention of many global users due to its insurmountable difficulty in contrast to the simple operation method.
In the Steam Early Access version of ALTF42, although users are only allowed to play certain stages of the game, they can experience most of the core systems. In this version, only two languages, Korean and English, are supported, and game systems such as items, costumes, traps, and supported languages will be gradually supplemented through regular updates.
Yoo Joon, Business Team Leader at Gravity, said, “Gravity is showcasing ALTF42, the official follow-up to ALTF4, which has been loved by many users across the world. I highly recommend trying out the game, as users can experience most of the game’s systems in advance, even in the Early Access version that will be released this time. Starting with ALTF42, we plan to introduce console titles of various genres sequentially, as we have signed global publishing contracts for these titles. We kindly request your continued interest and support.”
More information on ALTF42 Early Access is available at the official Stream website for ALTF42 (https://store.steampowered.com/app/2187230/ALTF42/) and inquiries on game publishing can be made via e-mail (startgravity@gravity.co.kr).
About Gravity
Gravity Co., Ltd is a Korean game company established in April 2000 and a global game company listed on NASDAQ (GRVY). The number of global cumulative accounts of Ragnarok IP, Gravity's representative IP, recorded more than 120 million as of September 30, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom